tirzepatide diabetes trial once weekly for the treatment of obesity in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Preliminary results on the Tirzepatide

However, the Wolverine Peptide is not appropriate for everyonepatients with active cancer, uncontrolled autoimmune disease, or complex medical conditions need careful evaluation before considering peptide therapy

PMID: 39721999 J Clin Invest Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations

In certain patients, it can cause brain swelling requiring immediate medical attention

While achieving a healthier weight often leads to improved hormonal balance and cardiovascular function, the process of losing weight can initially strain the body

In 2025, two retrospective studies were conducted to find any association between hair loss and GLP-1 medications